By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Oncology. According to news reporting out of Lodz, Poland, by NewsRx editors, research stated, "Chronic lymphocytic leukemia (CLL) is the most common leukemia in Europe and North America. For many years scientists and doctors have been working on introducing the most effective therapy into CLL as prognosis of survival time and the course of the disease differ among patients, which might pose a problem in treating."
Our news journalists obtained a quote from the research from Copernicus Memorial Hospital, "Nanotechnology is providing new insights into diagnosis and, compared with conventional treatments, more efficient treatments, which might improve patients' comfort by decreasing side effects. Among the various nanoparticles that are available, dendrimers are one of the most promising. The aim of this study was a preliminary assessment of the clinical value of treating CLL patients with fourth generation poly(propylene imine) (PPI) dendrimers-either unmodified (PPI-G4) or approximately 90% maltotriose-modified (PPI-G4-DS-Mal-III). PPI-G4-DS-Mal-III dendrimers have, in contrast to the cationic PPI-G4, a neutral surface charge and are characterized by low cyto-, geno-, and hematotoxicity in vitro and in vivo. For the in vitro study we used blood mononuclear cells collected from both untreated CLL patients and from healthy donors. Apoptosis was measured by an annexin-V (Ann-V)/propidium iodide (IP) assay, and mitochondrial membrane potential was estimated with use of Mito Tracker Red CMXRos. Presented results confirm the influence of dendrimers PPI-G4 and PPI-G4-DS-Mal-III on apoptosis and CLL lymphocytes viability in in vitro cultures. Both tested dendrimers demonstrated higher cytotoxicity to CLL cells than to healthy donors cells, whereas unmodified dendrimers were more hematotoxic."
According to the news editors, the research concluded: "The surface modification clearly makes glycodendrimers much more suitable for biomedical applications than unmodified PPI-G4; therefore further biological evaluations of these nanoparticles are conducted in our laboratories."
For more information on this research see: The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI. Molecular Pharmaceutics, 2013;10(6):2490-501. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
Our news journalists report that additional information may be obtained by contacting I. Franiak-Pietryga, Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Lodz, Poland. Additional authors for this research include E. Zio?kowska, B. Ziemba, D. Appelhans, B. Voit, M. Szewczyk, J. Gora-Tybor, T. Robak, B. Klajnert and M. Bryszewska (see also Oncology).
Keywords for this news article include: Lodz, Poland, Europe, Oncology, Hematology, Nanoparticle, Nanotechnology, Emerging Technologies, Chronic Lymphocytic Leukemia.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC